PRIME MEDICINE INC
PRMENASDAQ🏆 #2403 by market capEarnings Oct 30US Equity
$5.24▼ $0.13 (−2.33%)
Pre-market · at closeTrack PRME
Get earnings, price moves & breaking news on Telegram
24h▼ 2.3%
7d▲ 42.8%
14d▲ 51.0%
30d▲ 71.8%
ytd▲ 51.9%
1y▲ 20.7%
🏦Market Cap
$950M
Small Cap
📈Revenue Growth (YoY)
-17.9%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
193.7x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $5.20 – $5.91
- 52-Week Range
- $2.67 – $5.20
- Volume (shares)
- 686,568
- Avg Volume (shares)
- —
- Shares Outstanding
- 181.4M
- Next Earnings
- 2026-10-30
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 193.7x
- EPS (TTM)
- $-1.09
- Dividend Yield
- —
- Dilution (1yr)
- +25.4%
PRIME MEDICINE INC
PRMEFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$5M▲ +55.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-58.1%▼ −158.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$208M▲ +2.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$167M▲ +28.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
148.8M▲ +25.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$53M▼ −$195M YoY
StockOtter · stockotter.spaceAbout PRIME MEDICINE INC
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
20 analysts
Strong Buy6
Buy10
Hold4
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.